JP Morgan Chase
OCUL icon

JP Morgan Chase’s Ocular Therapeutix OCUL Stock Holding History

JP Morgan Chase’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,000
Closed -$70.1K – 7674
2025
Q3 		$70.1K Buy
+6,000
New +$71.7K ﹤0.01% 6095

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's OCUL Position: Q2 2026 in Review

JP Morgan Chase reduced its Ocular Therapeutix (OCUL) stake by 7.4% in Q2 2026, selling an estimated $348K and leaving 482,293 shares worth $4.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

JP Morgan Chase first reported a position in OCUL in Q1 2017 and has held it in 38 quarters since. The position peaked at $6.68M in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • JP Morgan Chase held 482,293 shares of Ocular Therapeutix worth $4.86M as of Q2 2026.
  • JP Morgan Chase sold 38,370 Ocular Therapeutix shares in Q2 2026, an estimated $348K.
  • Ocular Therapeutix made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3485 holding.
  • JP Morgan Chase first reported a position in Ocular Therapeutix in Q1 2017 and has held it in 38 quarters since.
  • JP Morgan Chase's Ocular Therapeutix position peaked at $6.68M in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.